Goodwin Advised Isomorphic Labs on Strategic AI-Driven Research Collaboration with Johnson & Johnson

Goodwin Advised Isomorphic Labs on Strategic AI-Driven Research Collaboration with Johnson & Johnson

Goodwin advised Isomorphic Labs on a strategic, cross-modality, multi-target research collaboration with Johnson & Johnson. The collaboration combines Isomorphic’s AI-first approach to drug discovery with Johnson & Johnson’s expertise in drug discovery and development. Under the terms of the collaboration, Isomorphic Labs will be responsible for in silico predictions and design, while Johnson & Johnson will conduct experimental assays and advance programs through development.

The Goodwin team was led by Noelle Dubiansky (Partner/ Technology & Life Sciences) and Katerina Stavrianidis (Associate/ Technology & Life Sciences) and consisted of John Yates (Partner/ Technology, Life Sciences Transaction), Evan De Ycaza (Associate/ Business Law), Daniel Karelitz (Partner/ Business Law), Eram Khan (Associate/ Business Law), and Bethany Withers (Partner/ Technology & IP, Strategic Transaction).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.